290

2019-yil dekabr oyida tan olingan va pandemiyaga sabab boʻlgan COVID-19 virusi global
miqyosda tez tarqaldi. Gipertenziya, qandli diabet va yurak-qon tomir kasalliklari kabi ilgari mavjud
bo'lgan kasalliklar COVID-19 bilan uning og'irligi va o'lim darajasining yuqoriligi sababli bog'liqdir.
Bundan tashqari, COVID-19 yurak-qon tomir asoratlari, jumladan, oʻtkir koronar sindrom, miokardit,
stress-kardiomiopatiya, aritmiya, kardiogen shok va yurak xuruji natijasida oʻtkir miokard
shakllanishiga turtki beradi. COVID-19 ning yurak-qon tomir o'zaro ta'siri og'ir o'tkir respirator
sindrom, yaqin Sharq respirator sindromi va gripp bilan o'xshashliklarga ega. Antikoagulyatsion
vositalar bilan qo'llab-quvvatlovchi davolashda, renin-angiotenzin-aldosteron sistemasining
ingibitorlarini doimiy ravishda qo'llashda, aritmiya monitoringi, immunosupressiya yoki modulyatsiya
va qon aylanishini mexanik qo'llab-quvvatlashda yurak-qon tomir tizimiga alohida e'tibor berilishi
kerak. Shunday qilib, ushbu maqolada biz COVID-19da yurak-qon tomir tizimidagi o'zgarishlarning
morfologik xususiyatlarini muhokama qilamiz.

  • Read count287
  • Date of publication12-12-2021
  • Main LanguageO'zbek
  • Pages52-60
Русский

Вирус COVID-19, который был обнаружен в декабре 2019 года и вызвал пандемию,
быстро распространился по всему миру. Ранее существовавшие состояния, такие как
гипертония, диабет и сердечно-сосудистые заболевания, связаны с COVID-19 из-за его тяжести
и высокого уровня смертности. Кроме того, COVID-19 может вызвать острый инфаркт
миокарда в результате сердечно-сосудистых осложнений, включая острый коронарный
синдром, миокардит, стрессовую кардиомиопатию, аритмии, кардиогенный шок и сердечный
приступ. Сердечно-сосудистые взаимодействия COVID-19 имеют сходство с тяжелым острым
респираторным синдромом, ближневосточным респираторным синдромом и гриппом. Особое
внимание следует уделять сердечно-сосудистой системе при поддерживающей терапии
антикоагулянтами, постоянном применении ингибиторов ренин-ангиотензин-
альдостероновой системы, мониторинге аритмии, иммуносупрессии или модуляции и
механической поддержке кровообращения. Таким образом, в этой статье мы обсуждаем
морфологические особенности изменений сердечно-сосудистой системы при COVID-19.

Ўзбек

2019-yil dekabr oyida tan olingan va pandemiyaga sabab boʻlgan COVID-19 virusi global
miqyosda tez tarqaldi. Gipertenziya, qandli diabet va yurak-qon tomir kasalliklari kabi ilgari mavjud
bo'lgan kasalliklar COVID-19 bilan uning og'irligi va o'lim darajasining yuqoriligi sababli bog'liqdir.
Bundan tashqari, COVID-19 yurak-qon tomir asoratlari, jumladan, oʻtkir koronar sindrom, miokardit,
stress-kardiomiopatiya, aritmiya, kardiogen shok va yurak xuruji natijasida oʻtkir miokard
shakllanishiga turtki beradi. COVID-19 ning yurak-qon tomir o'zaro ta'siri og'ir o'tkir respirator
sindrom, yaqin Sharq respirator sindromi va gripp bilan o'xshashliklarga ega. Antikoagulyatsion
vositalar bilan qo'llab-quvvatlovchi davolashda, renin-angiotenzin-aldosteron sistemasining
ingibitorlarini doimiy ravishda qo'llashda, aritmiya monitoringi, immunosupressiya yoki modulyatsiya
va qon aylanishini mexanik qo'llab-quvvatlashda yurak-qon tomir tizimiga alohida e'tibor berilishi
kerak. Shunday qilib, ushbu maqolada biz COVID-19da yurak-qon tomir tizimidagi o'zgarishlarning
morfologik xususiyatlarini muhokama qilamiz.

English

Since its recognition in December 2019, COVID-19 has rapidly spread globally causing a
pandemic. Pre-existing comorbidities such as hypertension, diabetes, and cardiovascular disease are
associated with a greater severity and higher fatality rate of COVID-19. Furthermore, COVID-19
contributes to cardiovascular complications, including acute myocardial injury as a result of acute
coronary syndrome, myocarditis, stress-cardiomyopathy, arrhythmias, cardiogenic shock, and cardiac
arrest. The cardiovascular interactions of COVID-19 have similarities to that of severe acute
respiratory syndrome, Middle East respiratory syndrome and influenza. Specific cardiovascular
considerations are also necessary in supportive treatment with anticoagulation, the continued use of
renin-angiotensin-aldosterone system inhibitors, arrhythmia monitoring, immunosuppression or
modulation, and mechanical circulatory support. Thus, in this article we will discuss morphological
features of changes in the cardiovascular system in COVID-19.

№ Name of reference
1 1. World Health Organization. WHO Director-General's opening remarks at the media briefing on COVID-19 - 11 March 2020. Available online at https://www.who.int/dg/speeches/detail/whodirector-general-s-opening-remarks-at-the- media-briefing-on-covid-19---1 march-2020, Accessed 4th Apr 2020
2 2. Coronavirus Disease 2019 (COVID-19). Centers for Disease Control and Prevention. https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/cases-in-us.html , Accessed 11th Apr 2020
3 3. World Health Organization Situation report https://www.who.int/docs/default- source/coronaviruse/situation-reports/20200403-sitrep-74-covid-19- mp.pdf?sfvrsn=4e043d03_4, Accessed 4th Apr 2020
4 4. E. Driggin, M.V. Madhavan, B. Bikdeli, et al. Cardiovascular considerations for patients, health care workers, and health systems during the coronavirus disease 2019 (COVID-19 pandemic
5 5. J Am Coll Cardiol (Mar 18 2020)[pii: S0735-1097(20)34637-4, in press] Z. Wu, J.M. McGoogan Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese Center for Disease Control and Prevention JAMA (Feb 24 2020), 10.1001/jama.2020.2648
6 6. Q. Ruan, K. Yang, W. Wang, L. Jiang, J. Song Clinical predictors of mortality due to COVID- 19 based on an analysis of data of 150 patients from Wuhan, China [published online ahead of print, 2020 Mar 3] Intensive Care Med (2020), pp. 1-3, 10.1007/s00134-020-05991-x
7 7. C. Huang, Y. Wang, X. Li, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China Lancet, 395 (2020), pp. 497-506
8 8. F. Zhou, T. Yu, R. Du, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study Lancet, 395 (10229) (Mar 28 2020), pp. 1054-1062
9 9. D. Wang, B. Hu, C. Hu, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China JAMA (Feb 7 2020), 10.1001/jama.2020.1585
10 10. Novel coronavirus (2019-nCoV) situation Report-1, 2020. Available: https://www.who.int/docs/default-source/coronaviruse/situation- reports/20200121-sitrep-1-2019-ncov.pdf?sfvrsn=20a99c10_4
11 11. Coronavirus COVID-19 global cases by the center for systems science AD engineering (CSSE) at Johns Hopkins University. Available: https://coronavirus.jhu.edu/map.html [Accessed 12 Apr].
12 12. Huang C , Wang Y , Li X , et al Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020;395:497–506. doi:10.1016/S0140- 6736(20)30183-5 pmid:http://www.ncbi.nlm.nih.gov/pubmed/31986264
13 13. Wang D , Hu B , Hu C , et al Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA 2020;323:1061– 9.doi:10.1001/jama.2020.1585 pmid:http://www.ncbi.nlm.nih.gov/pubmed/32031570
14 14. The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) — China, 2020. China CDC Weekly 2020;2:113–22
15 15. Guo T , Fan Y , Chen M , et al Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19). JAMA Cardiol 2020.doi:10.1001/jamacardio.2020.1017
16 16. Long, B., Brady, W. J., Koyfman, A., & Gottlieb, M. (2020). Cardiovascular complications in COVID-19. The American Journal of Emergency Medicine. doi:10.1016/j.ajem.2020.04.048
17 17. Hamming I, Timens W, Bulthuis ML, Lely AT, Navis G, van Goor H. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J Pathol Jun 2004;203(2):631–7.
18 18. Zhou P, Yang XL, Wang XG, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature Mar 2020;579(7798):270–3.
19 19. Ge XY, Li JL, Yang XL, et al. Isolation and characterization of a bat SARS-like coronavirus that uses the ACE2 receptor. Nature 2013;503:535–8.
20 20. Zhang H, Penninger JM, Li Y, Zhong N, Slutsky AS. Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target. Intensive Care Med Apr 2020;46(4):586–90.
21 21. Libby P, Simon DI. Inflammation and thrombosis: the clot thickens. Circulation 2001; 103:1718–20
22 22. Kwong JC, Schwartz KL, Campitelli MA, et al. Acute myocardial infarction after laboratory- confirmed influenza infection. N Engl J Med 2018;378:345–53.
23 23. Davis MM, Taubert K, Benin AL, et al. Influenza vaccination as secondary prevention for cardiovascular disease: a science advisory from the American Heart Association/ American College of Cardiology. J Am Coll Cardiol 2006;48:1498–502.
24 24. Chen L, Li X, Chen M, Feng Y, Xiong C. The ACE2 expression in human heart indicates new potential mechanism of heart injury among patients infected with SARS-CoV-2. Cardiovasc Res Mar 30 2020. https://doi.org/10.1093/cvr/cvaa078 [pii: cvaa078, Epub ahead of print].
25 25. Li B, Yang J, Zhao F, et al. Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China. Clin Res Cardiol Mar 11 2020. https://doi.org/10.1007/ s00392-020- 01626-9 [Epub ahead of print].
26 26. Murthy S, Gomersall CD, Fowler RA. Care for critically ill patients with COVID-19. JAMA Mar 11 2020. https://doi.org/10.1001/jama.2020.3633 [Epub ahead of print].
27 27. Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 2020;395:507–13.
28 28. Yang X, Yu Y, Xu J, et al. Clinical course and outcomes of critically ill patients with SARS- CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med Feb 24 2020. https://doi.org/10.1016/S2213-2600 (20)30079-5 [pii: S2213-2600(20)30079-5, Epub ahead of print].
29 29. Weiss P, Murdoch DR. Clinical course and mortality risk of severe COVID-19. Lancet 2020;395(10229):1014–5. https://doi.org/10.1016/S0140-6736(20)30633-4.
30 30. Intensive Care National Audit & Research Centre. ICNARC report on COVID-19 in critical care. March 27, 2020. Accessed March 30, 2020.
31 31. Alhogbani T. Acute myocarditis associated with novel middle east respiratory syndrome coronavirus. Ann Saudi Med 2016;36:78–80.
32 32. Chen C, Zhou Y, Wang DW. SARS-CoV-2: a potential novel etiology of fulminant myocarditis. Herz Mar 2020. https://doi.org/10.1007/s00059-020-04909-z [Epub ahead of print]
33 33. Liu K, Fang YY, Deng Y, et al. Clinical characteristics of novel coronavirus cases in tertiary hospitals in Hubei Province. Chin Med J (Engl) Feb 7 2020. https://doi.org/10. 1097/CM9.0000000000000744 [Epub ahead of print].
34 34. Xu Z, Shi L, Wang Y, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med Apr 2020;8(4):420–2.
35 35. Liu Y, Yang Y, Zhang C, et al. Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury. Sci China Life Sci 2020;63: 364–74.
36 36. Shi S, Qin M, Shen B, et al. Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China. JAMA Cardiol. doi:https://doi.org/10. 1001/jamacardio.2020.0950.
37 37. Guo T, Fan Y, Chen M, et al. Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19). JAMA Cardiol. doi:https://doi.org/10. 1001/jamacardio.2020.1017.
38 38. Corrales-Medina VF, Alvarez KN, Weissfeld LA, et al. Association between hospitalization for pneumonia and subsequent risk of cardiovascular disease. JAMA 2015; 313:264–74.
39 39. Welt FGP, Shah PB, Aronow HD, from the American College of Cardiology’s (ACC) Interventional Council and the Society of Cardiovascular Angiography and Intervention (SCAI), et al. Catheterization laboratory considerations during the coronavirus (COVID-19)pandemic: from ACC’s Interventional Council and SCAI. JACC 2020. https://doi.org/10.1016/j.jacc.2020.03.021.
40 40. Chen T, Wu D, Chen H, et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. BMJ Mar 26 2020;368:m1091.
41 41. Buzon J, Roignot O, Lemoine S, et al. Takotsubo cardiomyopathy triggered by influenza A virus. Intern Med 2015;54:2017–9.
42 42. Xie Y, Wang X, Yang P, Zhang S. COVID-19 complicated by acute pulmonary embolism. Radiology: Cardiothoracic Imaging 2020;2(2):e200067.
43 43. Danzi GB, Loffi M, Galeazzi G, Gherbesi E. Acute pulmonary embolism and COVID-19 pneumonia: a random association? Eur Heart J Mar 30 2020. https://doi.org/10. 1093/eurheartj/ehaa254 [pii: ehaa254, Epub ahead of print].
44 44. Chen J, Wang X, Zhang S, et al. Findings of acute pulmonary embolism in COVID-19 patients. Lancet Infectious Disease. [Available at SSRN: https://ssrn.com/abstract= 3548771 or http://dx.doi.org/10.2139/ssrn.3548771].
45 45. Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost Apr 2020;18(4):844–7.
46 46. Tang N, Bai H, Chen X, et al. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost Mar 27 2020. https://doi.org/10.1111/jth.14817 [Epub ahead of print].
47 47. Chavez S, Long B, Koyfman A, Liang S. Coronavirus disease (COVID-19): a primer for emergency physicians. American Journal of Emergency Medicine March 24, 2020. https://doi.org/10.1016/j.ajem.2020.03.036 Published online.
48 48. Elfiky AA. Anti-HCV, nucleotide inhibitors, repurposing against COVID-19. Life Sci 2020;248:117477.
49 49. Chu CM, Cheng VC, Hung IF, et al. Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings. Thorax 2004;59:252–6.
50 50. KALETRA(R) oral film coated tablets, oral solution, lopinavir ritonavir oral film coated tablets, oral solution. Product insert. North Chicago, IL: AbbVie Inc. (per FDA); 2013.
51 51. Page II RL, O’Bryant CL, Cheng D, et al. Drugs that may cause or exacerbate heart failure: a scientific statement from the American Heart Association. Circulation 2016; 134:e32–69.
52 52. Tonnesmann E, Kandolf R, Lewalter T. Chloroquine cardiomyopathy - a review of the literature. Immunopharmacol Immunotoxicol 2013;35:434–42
53 53. Khawaja, S. A., Mohan, P., Jabbour, R., Bampouri, T., Bowsher, G., Hassan, A. M. M., ... Mikhail, G. W. (2021). COVID-19 and its impact on the cardiovascular system. Open Heart, 8(1), e001472. doi:10.1136/openhrt-2020-001472
Waiting